巴西研究表明羟氯喹对治疗轻中症新冠肺炎无效-中新网 近日，一项巴西研究表明，羟氯喹对轻中症新冠肺炎患者无效。 该研究报告在《新英格兰医学杂志》 (New England Journal of Medicine)上发表。 巴研究人员将全国55家医院的667名患者分成三组，进行了临床试验；主要对比单独使用羟氯喹或结合其它抗生素阿奇霉素的治疗效果，分析是否有助于改善新冠肺炎轻度和中度患者的病情。 结果显示羟氯喹不仅没有治疗效果，反而可能对脏器产生损伤性副作用。 这项研究是由巴西多家权威医院如爱因斯坦医院(Hospital Israelita Albert Einstein) 、心脏病医院(HCor) 、叙利亚黎巴嫩医院(Hospital Sírio-Libanês)等与巴西临床研究所(BCRI)和巴西重症监护研究网络(BRICNet)联合完成。 当地时间25日，巴西总统博索纳罗通过社交平台宣布第4次核酸检测结果为阴性。 感染期间，博索纳罗一直服用羟氯喹并多次积极推广。 总台记者 赵艺君
Brazilian study shows that hydroxychloroquine is ineffective in treating patients with mild and moderate COVID-19 - www.chinanews.com Recently, a Brazilian research showed that hydroxychloroquine was ineffective for patients with mild and moderate COVID-19. The research report was published in the New England Journal of Medicine. Brazilian researchers divided 667 patients from 55 hospitals across the country into three groups and conducted clinical trials on them, and this research mainly compared the therapeutic effects of hydroxychloroquine alone or hydroxychloroquine combined with other antibiotics azithromycin, and analyzed whether hydroxychloroquine was helpful to improve the condition of mild and moderate patients in COVID-19. The research results showed that hydroxychloroquine not only had no therapeutic effect, but might have harmful side effects on organs. This research was completed by several authoritative hospitals in Brazil, such as Hospital Israelita Albert Einstein, HCor, and Hospital Sírio-Libanês, together with the Brazilian Clinical Research Institute (BCRI) and the Brazilian Intensive Care Research Network (BRICNet). On the 25th local time, Brazilian President Bolsonaro announced that his fourth nucleic acid testing result was negative through social platform. During his infection, Bolsonaro has been taking hydroxychloroquine and actively promoting it for many times. Zhao Yijun, Headquarters Reporter